159 results on '"Pratt, Edward"'
Search Results
2. Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist
3. Harvard East Asian Monographs
4. Glossary
5. Index
6. Works Cited
7. Notes
8. Title Page, Copyright, Dedication
9. 1: Political Authorities and the Rural Elite
10. 4: Rural Elites in Cotton Regions
11. Contents
12. Part I. The Political Economy of Japanese Protoindustrialization
13. 2: The Transformation of Regional Production
14. Part II. Case Studies
15. Acknowledgments
16. 5: Rural Elite in Silk Regions
17. 3: Markets
18. 6: Tea and Sake Elites
19. A Note on Japanese Names and Dates
20. Maps and Tables
21. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
22. Effects of Tirzepatide vs Semaglutide on β-cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test
23. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
24. Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes
25. Improvements in post‐challenge lipid response following tirzepatide treatment in patients with type 2 diabetes
26. Improvements in post‐challenge lipid response following tirzepatide treatment in patients with type 2 diabetes.
27. 52-OR: Effect of Oral Nonpeptide GLP-1 Receptor Agonist Orforglipron (LY3502970) in Participants with Obesity or Overweight—A Phase 2 Study
28. Tirzepatide Reduces Appetite, Energy Intake and Fat Mass in People with T2D
29. Tirzepatide reduces appetite, energy intake and fat mass in people with T2D
30. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
31. Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once‐weekly dosing for the treatment of patients with diabetes
32. sj-docx-1-dst-10.1177_19322968221145200 – Supplemental material for Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 Diabetes
33. Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants.
34. Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 Diabetes
35. 338-OR: Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People with T2D
36. 336-OR: A First-in-Human Single- and Multiple-Ascending Dose Study Evaluating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Nonpeptide GLP-1 Receptor Agonist in Healthy Subjects
37. 722-P: Tirzepatide Improves Multiple Aspects of Beta-Cell Function
38. Effect of Orforglipron versus Placebo and Dulaglutide on Glycemic Control and Body Weight in Patients with Type 2 Diabetes.
39. Basal Insulin Fc (BIF), A Novel Insulin Suited For Once Weekly Dosing For The Treatment of Patients With Diabetes Mellitus
40. Total Hip Arthroplasty
41. Contributors
42. Open Reduction and Internal Fixation of the Hip
43. Effects of Tirzepatide on Eating Behaviour: A Phase 1 Study in People Living with Obesity.
44. Effect of oral non-peptide GLP-1 receptor agonist orforglipron (LY3502970) in participants with obesity or overweight: A Phase 2 study.
45. A Long-Acting Glucose Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss Without Nausea or Vomiting.
46. A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves gastrointestinal tolerability of glucagon-like peptide 1 receptor agonist therapy.
47. An Unusual Outbreak of Hypoglycemia — A Correction
48. Tea and Sake Elites
49. Rural Elites in Silk Regions
50. Rural Elites in Cotton Regions
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.